Adaptive Biotechnologies (ADPT) Cash from Investing Activities (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash from Investing Activities across 9 years of filings, most recently posting -$43.5 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 1399.37% year-over-year to -$43.5 million; the TTM figure through Jun 2026 stood at -$25.3 million (down 144.92% YoY), while the FY2025 annual figure was $37.9 million, down 51.22% from the prior year.
• Cash from Investing Activities came in at -$43.5 million for Q2 2026 at Adaptive Biotechnologies, down from $9.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $63.0 million in Q1 2023 to a low of -$97.5 million in Q4 2022.
• Average Cash from Investing Activities over 5 years is $11.9 million, with a median of $13.2 million recorded in 2025.
• Year-over-year, Cash from Investing Activities surged 686.41% in 2023 and slumped 1399.37% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$97.5 million in 2022, then jumped by 103.29% to $3.2 million in 2023, then soared by 589.71% to $22.1 million in 2024, then plunged by 137.31% to -$8.3 million in 2025, then plunged by 426.87% to -$43.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$43.5 million in Q2 2026, $9.1 million in Q1 2026, and -$8.3 million in Q4 2025.